When the market is hot, you feel like you can do no wrong. Then, there’s a little hiccup and you quickly see how things can go South in a hurry. It’s important to know the fundamentals when you’re looking at longer-term investment ideas. Stocks with strong earnings trends are essential over the long run. At the end of the day, stocks really are a function of their earnings.At Zacks, stocks which are Zacks Rank #5 (Strong Sell) stocks are those with the weakest earnings trends. It’s important to understand w ...

AirSculpt Technologies, Inc. (AIRS) reported $47.61 million in revenue for the quarter ended December 2023, representing a year-over-year increase of 17%. EPS of $0.01 for the same period compares to $0.07 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $47.83 million, representing a surprise of -0.46%. The company delivered an EPS surprise of -90.91%, with the consensus EPS estimate being $0.11.While investors closely watch year-over-year changes in headline numbers -- revenue a ...

Financial Data and Key Metrics - Revenue for Q4 2023 was $47.6 million, a 17% increase YoY, driven by the addition of five de novo centers [18] - Adjusted EBITDA for Q4 2023 was $10.1 million, a 27.9% increase YoY, with a margin improvement of 180 basis points to 21.2% [20] - Full-year 2023 revenue was $196 million, a 16% increase YoY, meeting expectations, while adjusted EBITDA was $43.2 million, an 11.2% increase YoY, slightly below the updated guidance of at least $45 million [9] - Average revenue per case for Q4 2023 was $12,937, a 6.1% increase YoY, with rates expected to range between $12,000 and $13,000 [18] - Customer acquisition cost (CAC) for Q4 2023 was approximately $2,600 per case, up from $2,300 in the prior year due to increased brand awareness investments [19] Business Line Data and Key Metrics - The company opened five new centers in 2023, the highest number in its history, contributing to revenue growth [4] - Same-store revenue performance for Q4 2023 was -1.7%, below expectations, representing about one procedure per location per month [7] - The company expanded its product and service offerings by adding AirSculpt Lift, a facial fat transfer procedure [5] - The company's TAM (Total Addressable Market) was quantified at $9 billion, with potential for hundreds of AirSculpt centers globally [5] Market Data and Key Metrics - The company's brand awareness grew by 30% YoY, driven by brand-building activities [5] - The company is expanding into new markets, including Birmingham, Michigan; Deerfield, Illinois; Kansas City, Kansas; White Plains, New York; and Columbus, Ohio, with a sixth location to be announced later [12] - The company is focusing on multi-site markets, such as Chicago and New York, to leverage scale and operational efficiency [12] Company Strategy and Industry Competition - The company's strategy focuses on strengthening the AirSculpt brand, accelerating store openings, and enhancing profitability both domestically and internationally [6] - The company plans to open six de novo centers in 2024, with a focus on same-store growth and improving patient acquisition efforts [10][12] - The company is transitioning to an enterprise-wide Salesforce CRM implementation to improve sales and marketing processes and patient experience [14] - The company is focusing on cost management, with a goal of delivering $5 million in-year savings for 2024, while reinvesting savings into growth initiatives [15] Management Commentary on Operating Environment and Future Outlook - Management is optimistic about the company's future, citing a $9 billion TAM and the potential for significant growth [10] - The company expects a robust season in Q1 2024, with performance built into the 2024 outlook [8] - Management highlighted the importance of brand awareness investments, which are expected to drive long-term benefits despite short-term cost impacts [32] Other Important Information - The company has safely completed over 50,000 procedures, with patient safety and well-being as a top priority [5] - The company's leverage ratio at the end of Q4 2023 was 1.4x, with gross debt outstanding at $72.9 million [22] - The company's 2024 revenue guidance is approximately $220 million, representing a 12% increase YoY, with adjusted EBITDA guidance of $50 million, a 15.6% increase YoY [23] Q&A Session Summary Question: Response to the short-seller report - Management dismissed the short-seller report as containing inaccuracies and misleading information, emphasizing the company's commitment to patient safety and transparency [26] Question: Seasonality and pricing impact on Q4 2023 - Management noted no significant seasonality or discounting impact on Q4 2023 rates, with average revenue per case remaining consistent [28][30] Question: Brand awareness investment timing - Management explained that the decision to accelerate brand awareness investments in Q4 2023 was driven by strong demand, with the investment seen as a long-term benefit despite short-term cost impacts [32] Question: Variances from IPO forecasts - Management acknowledged softer same-store revenue growth and higher-than-expected corporate and brand awareness investments compared to the original IPO model [35] Question: Market expansion concerns - Management expressed confidence in the new markets, citing strong performance in recent openings and the potential for multi-site market expansion [38] Question: Pricing strategy - Management indicated that pricing is complex due to the bespoke nature of procedures but sees potential for future pricing adjustments, though no immediate changes are planned [43] Closing Remarks - Management thanked participants and expressed optimism for the company's future [46]

AirSculpt Technologies, Inc. (AIRS) came out with quarterly earnings of $0.01 per share, missing the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.07 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -90.91%. A quarter ago, it was expected that this company would post earnings of $0.09 per share when it actually produced earnings of $0.05, delivering a surprise of -44.44%.Over the last four quarter ...

MIAMI BEACH, Fla., Feb. 27, 2024 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (NASDAQ:AIRS)("AirSculpt" or the "Company"), a national provider of premium body contouring procedures, today announced results for the fourth quarter and full year ended December 31, 2023. Fourth quarter revenue increased 17.0% to $47.6 million and full year increased 16.1% to $195.9 million from the prior year periodsFourth quarter net loss improved $2.6 million to $4.6 million and full year net loss improved $10.2 million t ...

Exhibit 99.1 AirSculpt Technologies Reports Double Digit Revenue Growth for the Fourth Quarter and Full Year 2023 MIAMI BEACH, Fla., February 27, 2024 (GLOBE NEWSWIRE) – AirSculpt Technologies, Inc. (NASDAQ:AIRS)("AirSculpt" or the "Company"), a national provider of premium body contouring procedures, today announced results for the fourth quarter and full year ended December 31, 2023. "We are pleased with our fourth quarter results highlighted by growth of 17% in revenue and 28% in adjusted EBITDA as compa ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________. Commission file number: 001-40973 AirSculpt Technologies, Inc. (Exact name of registrant as specified in its charter) | ...

ATLANTA, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether AirSculpt Technologies, Inc. ("AirSculpt" or the "Company") (NASDAQ:AIRS) complied with federal securities laws. On February 23, 2024, Fuzzy Panda Research published a report alleging several issues, including the use of "suspect doctors with questionable credentials," and the existence of "multiple other never-before-reported malpractice lawsuits against the [C]ompany." Following this news, the Company's stock price de ...

MIAMI BEACH, Fla., Jan. 31, 2024 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. ("AirSculpt") (NASDAQ:AIRS), a national provider of premium body contouring procedures, today announced it will report fourth quarter 2023 financial results before market open on Tuesday, February 27, 2024, to be followed by a conference call on the same day at 8:30 a.m. Eastern Time. The conference call can be accessed by dialing 1-877-407-9716 (toll-free domestic) or 1-201-493-6779 (international) using the conference ID 137 ...

MIAMI BEACH, Fla., Jan. 31, 2024 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (“AirSculpt”) (NASDAQ: AIRS), a national provider of premium body contouring procedures, today announced it will report fourth quarter 2023 financial results before market open on Tuesday, February 27, 2024, to be followed by a conference call on the same day at 8:30 a.m. Eastern Time. The conference call can be accessed by dialing 1-877-407-9716 (toll-free domestic) or 1-201-493-6779 (international) using the conference ID 13 ...